Last reviewed · How we verify
Amzeeq 4% Topical Foam
Amzeeq is a topical foam formulation of minocycline that reduces inflammation and bacterial colonization in acne by inhibiting bacterial protein synthesis and suppressing inflammatory mediators.
Amzeeq is a topical foam formulation of minocycline that reduces inflammation and bacterial colonization in acne by inhibiting bacterial protein synthesis and suppressing inflammatory mediators. Used for Acne vulgaris.
At a glance
| Generic name | Amzeeq 4% Topical Foam |
|---|---|
| Also known as | minocycline |
| Sponsor | Edward Lain, MD |
| Drug class | Tetracycline antibiotic |
| Target | Bacterial 30S ribosomal subunit; matrix metalloproteinases |
| Modality | Small molecule |
| Therapeutic area | Dermatology |
| Phase | FDA-approved |
Mechanism of action
Minocycline is a tetracycline antibiotic that penetrates sebaceous follicles and exerts both antimicrobial effects against Cutibacterium acnes and anti-inflammatory effects by inhibiting matrix metalloproteinases and reducing cytokine production. The foam formulation provides enhanced penetration and cosmetic acceptability for topical delivery to acne-prone skin.
Approved indications
- Acne vulgaris
Common side effects
- Application site irritation
- Erythema
- Dryness
- Pruritus
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Amzeeq 4% Topical Foam CI brief — competitive landscape report
- Amzeeq 4% Topical Foam updates RSS · CI watch RSS
- Edward Lain, MD portfolio CI